---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-180435"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T13:47:01.908884+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eiger appoints David Apelian as permanent CEO; grants 750,000 stock options

## Summary
- David Apelian, Interim CEO since Dec 2022, named CEO effective June 28, 2023; remains on Board.
- Annual salary of $650,000 with bonus target of 60% of base salary.
- Grant of nonstatutory stock options for 750,000 shares vesting monthly over 48 months.
- Severance includes 12 months salary plus prorated target bonus on termination without cause or for good reason.
- Change-in-control severance: 18 months salary, full equity acceleration, COBRA coverage up to 18 months.

## SEC filing metadata
- accession: 0001193125-23-180435
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312523180435/0001193125-23-180435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312523180435/d503710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-180435
- JSON: https://secwatch.observer/filing/0001193125-23-180435.json
- Plain text: https://secwatch.observer/filing/0001193125-23-180435.txt

## Key facts
- Executive change
  David Apelian was appointed as Chief Executive Officer at Eiger BioPharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On June 28, 2023, the Board of Directors (the “ Board ”) of Eiger BioPharmaceuticals, Inc. (the “ Company ”) appointed David Apelian, the Company’s current Interim Chief Executive Officer, to serve as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312523180435/0001193125-23-180435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.